Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...

In interviews with Reuters, eight U.S. obesity specialists at universities and large health systems described a different ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

Viking says an early-stage study of its obesity pill VK2735 showed adults on the highest dosage lost 8.2% of their body ...

(Reuters) -Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce ...

Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed a "shocking first miss" during its most recent ...

Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...

Novo Nordisk (NVO) posts Q3 sales for its weight loss drug Wegovy, contrasting rival Eli Lilly's (LLY) quarterly miss for its obesity drug, Zepbound. Read more here.

Some patients are using lower-than-recommended dosages of generic weight-loss drugs to slim down ... Last week, the Food and ...

These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...